In vitro predictive models of particle-induced granulomas

03:113 years ago

Léa Hiéronimus is a PhD student at the Louvain centre for Toxicology and Applied Pharmacology (LTAP, UCLouvain, Belgium). Léa is working in François Huaux's team, where we are trying to better understand how certain inhaled particles exert their toxicity. The goal is to better diagnose and treat individuals exposed to particles, but also to identify the particle characteristics which induce, or do not induce, toxic effects. For this, Léa studies a very particular cell type which seems to be involved in particle responses. Indeed, we have found the specific accumulation of the innate subset of B-lymphocytes called “B-1 lymphocytes”, which occurred during granuloma formation/maturation induced by inhaled particles in mice. According to the literature, this accumulation can be attributed to their migration from mesothelial cavities such as the peritoneum, acting as a reservoir.
In addition to conventional particles-induced granulomas, which formation rely on macrophages responses, we developed new models relying on B-1 lymphocytes. Indeed, B-1 lymphocytes show a unique clustering property, that is not observed using macrophages or other subsets of B-lymphocytes (conventional B-2 lymphocytes) as purified B-1 lymphocytes regroup granuloma-inducing particles (carbon nanotubes CNT7, crocidolite asbestos, micrometric silica MinUSil and MSS, cobalt oxide,…) but not carbon black, a particle not-inducing granuloma in vivo. Additionally, we developed a model aiming to recapitulate the lung after B-1 lymphocytes migration and found that macrophages and epithelial cells (MHS and LA4 cell lines) where grouped to form spheroids when in coculture with B-1 and not B-2 lymphocytes.
These models will serve as tools to identify new mediators of granuloma formation, which could serve as biomarkers and/or therapeutic targets for exposed individuals. On the other hand, we aim to propose new bioassays for the prediction of granuloma-inducing materials using alternative models.

Lab website: https://uclouvain.be/en/research-institutes/irec/ltap
Contact: lea.hieronimus@uclouvain.be

Related

The NAM Navigator: A unique repository for information on the validation and acceptance of New Approach Methodologies
Projects and initiatives
HealthToxicology

The NAM Navigator: A unique repository for information on the validation and acceptance of New Approach Methodologies

The NAM navigator is an innovative knowledge portal to navigate you to and through valuable information on the development, standardization, validation and acceptance of New Approach Methodologies (NAM). The NAM Navigator acts as an online guide that provides specific information needed in each of these steps, thereby increasing the broad use of animal-free innovations. Follow the link in the video to start navigating!
02:136 days ago
VHP4Safety project
Projects and initiatives
HealthToxicologyIn vitroIn silico

VHP4Safety project

The safety testing of chemicals and pharmaceuticals traditionally relies on animal studies. However, these raise ethical concerns and often fail to accurately predict human responses. New scientific developments offer opportunities to build a Virtual Human Platform (VHP) for safety assessment, a platform that enables assessment based solely on human physiology and biology, integrating data from in vitro and in silico models. This video explains how we are developing the VHP through an interdisciplinary approach. Read the paper in the videolink or visit or VHP4Safety (https://vhp4safety.nl/) for more information.
03:1612 days ago
AI agents for safer science: How AI is Changing Chemical Risk Assessment
Innovation examples
HealthToxicologyIn silico

AI agents for safer science: How AI is Changing Chemical Risk Assessment

This video introduces a novel approach to chemical safety, where intelligent digital agents guided by large language models support scientists in making faster, more transparent decisions. By automating complex workflows and integrating tools like the OECD QSAR Toolbox, these agentic systems help prioritise research, reduce reliance on animal testing, and pave the way for safer, more sustainable innovation.
02:5620 days ago
User Research in developing the virtual human platform
Innovation examples
ToxicologyPolicy

User Research in developing the virtual human platform

Digital tools can support the phasing out of animal-based tests and data in chemical risk assessment. This is one of the core promises of the Virtual Human Platform. The potential contribution of digitalization is linked to the acceptance and adoption of tools, methods, and data by stakeholders in several societal sectors. To facilitate the integration of stakeholders in the configuration of digital tools, Dr. Isaac Ortega Alvarado and colleagues gather insights from risk assessors in their role as users. Risk assessors are the ones who actualize chemical risk assessment and its standards through their practices. With this perspective, this research contributes to understanding the development and implementation of digital tools as embedded in social processes of construction and reception.
01:1542 days ago